Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310107855> ?p ?o ?g. }
- W4310107855 endingPage "3252" @default.
- W4310107855 startingPage "3250" @default.
- W4310107855 abstract "Background: The combination of cytotoxic chemotherapy with a BCR::ABL1 tyrosine kinase inhibitor (TKI) has historically been standard of care for patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib is 3rd generation TKI with more potent BCR::ABL1 inhibition than earlier-generation TKIs. Ponatinib also suppresses T315I clones, which are responsible for most relapses with other TKIs. Here we present the 6-year follow-up results of hyper-CVAD plus ponatinib for patients with newly diagnosed Ph+ ALL. Methods: This was a phase 2, single-arm study to evaluate the efficacy and safety of hyper-CVAD with ponatinib in adults with newly diagnosed Ph+ ALL. Pts age 18 years or older with previously untreated Ph+ ALL were eligible; pts who had received 1 to 2 courses of prior chemotherapy, with or without a TKI, were also eligible. Pts were required to have an ECOG performance status of 2 or less, bilirubin <3mg/dl, creatinine <3mg/dl, and normal cardiac function. Pts received hyper-CVAD alternating with high-dose methotrexate and cytarabine for 8 cycles. Initially, ponatinib was given at a dose of 45 mg daily. Due to 2 deaths due to cardiovascular events related to ponatinib, beginning with pt #37, the protocol was amended. After the amendment, ponatinib was administered at a dose of 45 mg for 14 days in cycle 1, then 30mg daily once patients achieved CR and 15mg daily once a complete molecular response (CMR) was achieved. Maintenance therapy was given for 2 years, vincristine, prednisone and ponatinib. Pts received 12 doses of intrathecal chemotherapy with alternating doses of cytarabine and methotrexate. Results: 86 pts were treated. Pts characteristics are summarized in Table 1. The median age was 46 years (range 21-80). Sixty-six pts (77%) had received no prior ALL-directed therapy, and 20 pts (23%) had received 1-2 courses of therapy prior to enrollment. Among these 20 pts, 18 were in CR and 2 had persistent disease at the time of enrollment. Sixty three pts (73%) had a p190 transcript, and 21 (24%) had a p210 transcript. Among 68 pts with active disease at enrollment, all pts achieved CR. Among 54 pts evaluable for cytogenetic response, all pts achieved complete cytogenetic response, including 50 pts (93%) after 1 cycle. Among 85 pts evaluable for molecular response, 83 pts (98%) achieved at least a major molecular response and 73 pts (86%) achieved a CMR. No pts died in the first 4 weeks of therapy. After a median follow up of 75 months (range, 16-123+ months), the 5-year overall survival (OS) and relapse-free survival rates were 75% and 68%, respectively (Figure 1). Twenty pts (23%) underwent stem cell transplantation (SCT) in first remission (5 of whom relapsed post SCT and 1 of whom died from post-SCT complications), 10 pts (12%) died in CR, 13 pts (19%) relapsed without SCT, and 43 pts (50%) are in ongoing remission without SCT. Of the relapsed pts, 5 were on ponatinib at the time of relapse, 2 of whom acquired an E255K kinase domain mutation at relapse; and 5 were on imatinib or dasatinib at the time of relapse, 3 of whom acquired a T315I kinase domain mutation. Among the 10 deaths in CR, 2 were treatment-related (both due to myocardial infarction before the amendment to implement lower doses of ponatinib). In a 8-month landmark analysis, the 5-year OS for pts without ASCT and with ASCT were 87% and 70%, respectively (p =0.09). Among the pts who are in ongoing remission without ASCT, 3 received subsequent therapy for MRD-positive disease. The most common grade ≥3 AE was infections and/or febrile neutropenia, seen in 82 pts (95%). Other grade ≥3 AEs including elevated transaminases in 25 pts (29%), increased amylase and/or lipase in 15 (17%), hyperbilirubinemia in 13 pts (15%), and clinical pancreatitis in 13 pts (15%). Five pts (6%) had a grade ≥3 venous thrombotic event, and 5 pts (6%) had a grade ≥3 arterial cardiovascular event. Two patients died from ponatinib-related cardiovascular complications, both from MI during cycle 2. Conclusion: The combination of hyper-CVAD and ponatinib results deep and durable remissions in pts with newly diagnosed Ph+ ALL. The overall CMR rate was 86% and the 5-year OS was 75%, which compares favorably with regimens using first- or second-generation TKIs in this population. The combination was safe; the use of lower doses of ponatinib maintained efficacy and mitigated the risk of ponatinib-related toxicity. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
- W4310107855 created "2022-11-30" @default.
- W4310107855 creator A5000750846 @default.
- W4310107855 creator A5010786159 @default.
- W4310107855 creator A5020340537 @default.
- W4310107855 creator A5021380291 @default.
- W4310107855 creator A5029750735 @default.
- W4310107855 creator A5041470459 @default.
- W4310107855 creator A5043585566 @default.
- W4310107855 creator A5049385583 @default.
- W4310107855 creator A5050041791 @default.
- W4310107855 creator A5054395583 @default.
- W4310107855 creator A5058294747 @default.
- W4310107855 creator A5059091760 @default.
- W4310107855 creator A5060610152 @default.
- W4310107855 creator A5061026876 @default.
- W4310107855 creator A5070528077 @default.
- W4310107855 creator A5077963154 @default.
- W4310107855 creator A5087551533 @default.
- W4310107855 creator A5088307376 @default.
- W4310107855 creator A5089428686 @default.
- W4310107855 creator A5091492845 @default.
- W4310107855 creator A5091723676 @default.
- W4310107855 date "2022-11-15" @default.
- W4310107855 modified "2023-10-15" @default.
- W4310107855 title "Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results" @default.
- W4310107855 doi "https://doi.org/10.1182/blood-2022-167761" @default.
- W4310107855 hasPublicationYear "2022" @default.
- W4310107855 type Work @default.
- W4310107855 citedByCount "0" @default.
- W4310107855 crossrefType "journal-article" @default.
- W4310107855 hasAuthorship W4310107855A5000750846 @default.
- W4310107855 hasAuthorship W4310107855A5010786159 @default.
- W4310107855 hasAuthorship W4310107855A5020340537 @default.
- W4310107855 hasAuthorship W4310107855A5021380291 @default.
- W4310107855 hasAuthorship W4310107855A5029750735 @default.
- W4310107855 hasAuthorship W4310107855A5041470459 @default.
- W4310107855 hasAuthorship W4310107855A5043585566 @default.
- W4310107855 hasAuthorship W4310107855A5049385583 @default.
- W4310107855 hasAuthorship W4310107855A5050041791 @default.
- W4310107855 hasAuthorship W4310107855A5054395583 @default.
- W4310107855 hasAuthorship W4310107855A5058294747 @default.
- W4310107855 hasAuthorship W4310107855A5059091760 @default.
- W4310107855 hasAuthorship W4310107855A5060610152 @default.
- W4310107855 hasAuthorship W4310107855A5061026876 @default.
- W4310107855 hasAuthorship W4310107855A5070528077 @default.
- W4310107855 hasAuthorship W4310107855A5077963154 @default.
- W4310107855 hasAuthorship W4310107855A5087551533 @default.
- W4310107855 hasAuthorship W4310107855A5088307376 @default.
- W4310107855 hasAuthorship W4310107855A5089428686 @default.
- W4310107855 hasAuthorship W4310107855A5091492845 @default.
- W4310107855 hasAuthorship W4310107855A5091723676 @default.
- W4310107855 hasBestOaLocation W43101078551 @default.
- W4310107855 hasConcept C104317684 @default.
- W4310107855 hasConcept C126322002 @default.
- W4310107855 hasConcept C138626823 @default.
- W4310107855 hasConcept C143998085 @default.
- W4310107855 hasConcept C187212893 @default.
- W4310107855 hasConcept C2777583451 @default.
- W4310107855 hasConcept C2778461978 @default.
- W4310107855 hasConcept C2778729363 @default.
- W4310107855 hasConcept C2778904597 @default.
- W4310107855 hasConcept C2779536868 @default.
- W4310107855 hasConcept C2780381907 @default.
- W4310107855 hasConcept C2909962599 @default.
- W4310107855 hasConcept C54355233 @default.
- W4310107855 hasConcept C71924100 @default.
- W4310107855 hasConcept C86803240 @default.
- W4310107855 hasConceptScore W4310107855C104317684 @default.
- W4310107855 hasConceptScore W4310107855C126322002 @default.
- W4310107855 hasConceptScore W4310107855C138626823 @default.
- W4310107855 hasConceptScore W4310107855C143998085 @default.
- W4310107855 hasConceptScore W4310107855C187212893 @default.
- W4310107855 hasConceptScore W4310107855C2777583451 @default.
- W4310107855 hasConceptScore W4310107855C2778461978 @default.
- W4310107855 hasConceptScore W4310107855C2778729363 @default.
- W4310107855 hasConceptScore W4310107855C2778904597 @default.
- W4310107855 hasConceptScore W4310107855C2779536868 @default.
- W4310107855 hasConceptScore W4310107855C2780381907 @default.
- W4310107855 hasConceptScore W4310107855C2909962599 @default.
- W4310107855 hasConceptScore W4310107855C54355233 @default.
- W4310107855 hasConceptScore W4310107855C71924100 @default.
- W4310107855 hasConceptScore W4310107855C86803240 @default.
- W4310107855 hasIssue "Supplement 1" @default.
- W4310107855 hasLocation W43101078551 @default.
- W4310107855 hasOpenAccess W4310107855 @default.
- W4310107855 hasPrimaryLocation W43101078551 @default.
- W4310107855 hasRelatedWork W2753478539 @default.
- W4310107855 hasRelatedWork W2753605673 @default.
- W4310107855 hasRelatedWork W3160862844 @default.
- W4310107855 hasRelatedWork W3195294068 @default.
- W4310107855 hasRelatedWork W3215637673 @default.
- W4310107855 hasRelatedWork W4200125483 @default.
- W4310107855 hasRelatedWork W4223421149 @default.
- W4310107855 hasRelatedWork W4283362794 @default.
- W4310107855 hasRelatedWork W4286512586 @default.
- W4310107855 hasRelatedWork W4296532741 @default.
- W4310107855 hasVolume "140" @default.